• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Operating Officer Lachapelle Robin exercised 27,566 shares at a strike of $3.28, increasing direct ownership by 28% to 124,583 units (SEC Form 4)

    9/23/24 6:14:19 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LaChapelle Robin

    (Last) (First) (Middle)
    C/O ARRIVENT BIOPHARMA, INC.
    18 CAMPUS BOULEVARD, SUITE 100

    (Street)
    NEWTOWN SQUARE PA 19073

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ArriVent BioPharma, Inc. [ AVBP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/19/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/19/2024 M 2,700 A $6.24 99,717 D
    Common Stock 09/19/2024 M 2,867 A $2.28 102,584 D
    Common Stock 09/19/2024 M 7,164 A $2.28 109,748 D
    Common Stock 09/19/2024 M 2,471 A $2.28 112,219 D
    Common Stock 09/19/2024 M 12,364 A $3.65 124,583 D
    Common Stock 394,477 I Held by The MAKS Yao Trust(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $2.28 09/19/2024 M 2,471 (2) 09/07/2031 Common Stock 2,471 $0 2,460 D
    Stock Option (right to buy) $2.28 09/19/2024 M 2,867 (3) 01/31/2032 Common Stock 2,867 $0 22,637 D
    Stock Option (right to buy) $2.28 09/19/2024 M 7,164 (3) 01/31/2032 Common Stock 7,164 $0 15,473 D
    Stock Option (right to buy) $3.65 09/19/2024 M 12,364 (4) 01/31/2033 Common Stock 12,364 $0 18,865 D
    Stock Option (right to buy) $6.24 09/19/2024 M 2,700 (5) 08/21/2033 Common Stock 2,700 $0 56,471 D
    Explanation of Responses:
    1. The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.
    2. The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
    3. The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
    4. The shares underlying this option vested as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
    5. The shares underlying this option vested as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
    By: /s/ James Kastenmayer, Attorney-in-Fact For: Robin LaChapelle 09/23/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    2/20/2024$35.00Buy
    Jefferies
    2/20/2024$27.00Buy
    Goldman
    2/20/2024$30.00Buy
    Citigroup
    More analyst ratings

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ArriVent BioPharma Reports First Quarter 2025 Financial Results

      Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

      5/12/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

      4/28/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Reports Full Year 2024 Financial Results

      First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollmentSelected next-generation ADC candidate ARR-002 for IND enabling studiesCash and cash equivalents of $266.5 million as of December 31, 2024 NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financia

      3/3/25 7:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Leadership Updates

    Live Leadership Updates

    See more
    • ArriVent BioPharma Reports First Quarter 2025 Financial Results

      Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

      5/12/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

      4/28/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent Appoints John Hohneker, M.D., to its Board of Directors

      NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. "We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, includin

      5/16/24 4:05:00 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    SEC Filings

    See more
    • SEC Form 10-Q filed by ArriVent BioPharma Inc.

      10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)

      5/12/25 9:35:57 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

      5/12/25 8:00:19 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ArriVent BioPharma Inc.

      DEFA14A - ArriVent BioPharma, Inc. (0001868279) (Filer)

      4/28/25 4:20:18 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Parsey Merdad

      4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

      4/29/25 4:51:43 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Parsey Merdad

      3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

      4/29/25 4:49:46 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Yao Zhengbin

      4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

      2/14/25 4:27:36 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ArriVent BioPharma with a new price target

      B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00

      3/20/25 7:59:08 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on ArriVent BioPharma with a new price target

      Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

      3/10/25 7:18:09 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on ArriVent BioPharma with a new price target

      Oppenheimer initiated coverage of ArriVent BioPharma with a rating of Outperform and set a new price target of $35.00

      7/22/24 7:50:34 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ArriVent BioPharma Inc.

      SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

      12/4/24 4:32:39 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ArriVent BioPharma Inc.

      SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

      11/14/24 4:33:47 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ArriVent BioPharma Inc.

      SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

      11/12/24 2:45:16 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care